[1]王红芳,杨冠华,王明磊,等.应用诺模图和人工神经网络模型预测血管旁肝细胞癌射频消融术后局部复发[J].介入放射学杂志,2026,(06):633-639.[doi:10.3969/j.issn.1008-794X.2026.06.010 ]
　WANG Hongfang,YANG Guanhua,WANG Minglei,et al.Application of nomogram and artificial neural network models in predicting local recurrence of paravascular hepatocellular carcinoma after radiofrequency ablation[J].J Intervent Med,2026,(06):633-639.[doi:10.3969/j.issn.1008-794X.2026.06.010 ]
点击复制

应用诺模图和人工神经网络模型预测血管旁肝细胞癌射频消融术后局部复发()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年06
页码:
633-639
栏目:
临床研究
出版日期:
2026-06-17

文章信息/Info

Title:
Application of nomogram and artificial neural network models in predicting local recurrence of paravascular hepatocellular carcinoma after radiofrequency ablation
文章编号:
1008-794X(2026)-006-0633-07
作者:
王红芳;  杨冠华;  王明磊;  王梓玉;  吕昕芮;  陈 勇
750004 宁夏回族自治区银川 宁夏医科大学第一临床医学院(王红芳、杨冠华、王明磊、王梓玉、吕昕芮); 宁夏医科大学总医院放射介入科(陈 勇)
Author(s):
WANG Hongfang; YANG Guanhua; WANG Minglei; WANG Ziyu; LV Xinrui; CHEN Yong.
The First Clinical Medical College of Ningxia Medical University,Yinchuan,the Ningxia Hui Autonomous Region 750004,China
关键词:
肝细胞癌;  射频消融;  局部复发;  人工神经网络;  诺模图
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2026.06.010
文献标志码:
B
摘要:
目的 探讨血管旁肝细胞癌(p-HCC)患者射频消融(RFA)术后短期局部复发(LR)的危险因素,并构建诺模图和人工神经网络(ANN)模型。方法 回顾性分析2017年1月至2022年6月于宁夏医科大学总医院行RFA治疗的89例p-HCC患者的临床资料。根据RFA术后12个月内患者是否有LR,将患者分为LR组和非LR组。采用单因素和多因素分析确定p-HCC患者RFA术后LR的危险因素,以此构建诺模图和ANN模型,并采用内部验证评价模型预测效能。结果 多因素分析结果显示,肿瘤与血管间最短距离(OR=0.71,95%CI:0.546～0.911)是p-HCC患者经RFA术后LR的保护因素(P<0.05),肿瘤直径>2 cm(OR=3.42,95%CI:1.127～10.342)、瘤周血管数量(OR=2.25,95%CI:1.132～4.484)和消融边界<5 mm(OR=3.51,95%CI:1.137～10.845)是LR的独立危险因素(均P<0.05)。构建的诺模图ROC曲线下面积为0.859(95%CI:0.778～0.941),敏感度为0.918,特异度为0.750。Hosmer-Lemeshow拟合优度检验提示模型预测结果与实际结果间差异无统计学意义(χ2=13.313,P>0.05)。校准曲线、临床决策曲线和临床影响曲线表明,诺模图具有较好预测准确性和临床实用性。构建的ANN模型显示,瘤周血管数量和肿瘤与血管间最短距离在预测LR风险中所占权重最大。结论 肿瘤直径、瘤周血管数量、肿瘤与血管间最短距离和消融边界<5 mm是p-HCC患者经RFA术后短期LR的预测因素,基于以上因素构建的诺模图可有效预测LR风险。ANN模型显示瘤周血管数量和肿瘤与血管间最短距离在预测LR风险中所占权重最大。

参考文献/References:

[1] 朱诗迪,郑 琳.经皮穿刺热消融术在肝细胞癌中的临床应用进展[J].介入放射学杂志,2022,31:1224-1227.
Zhu SD,Zheng L.Advances in clinical application of percutaneous thermal ablation for hepatocellular carcinoma[J].J Interv Radiol,2022,31:1224-1227.
[2]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华肝脏病杂志,2022,30:367-388.
Medical Administration Bureau of the National Health Commission of the People's Republic of China.Guideline for diagnosis and treatment of primary liver cancer(2022 edition)[J].Chin J Hepatol,2022,30:367-388.
[3]Ward EM,Sherif AE,O'neill S,et al.Clinical outcomes of ablation compared with resection for single hepatocellular carcinoma lesions,as a primary treatment or bridging to liver transplantation:a retrospective comparative study[J].Ann Transplant,2021,26:e931980.
[4]王晓维,蒋逢辰,周水平,等.肝动脉栓塞化疗术联合微波消融治疗早期原发性肝癌的疗效观察[J].介入放射学杂志,2024,33:488-494.
Wang XW,Jiang FC,Zhou SP,et al.Transcatheter hepatic arterial chemoembolization combined with microwave ablation for the treatment of early primary hepatocellular carcinoma:observation of its efficacy[J].J Interv Radiol,2024,33:488-494.
[5]Chen R,Hou B,Zhou Y,et al.Recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma:Analysis of the pattern and risk factors[J].Front Oncol,2023,13:1018715.
[6]Zhang Z,Yu J,Liu S,et al.Multiparametric liver MRI for predicting early recurrence of hepatocellular carcinoma after microwave ablation[J].Cancer Imaging,2022,22:42.
[7]何 坤,何泳铸,胡泽民,等.肝癌射频消融术后复发危险因素分析及术前预测评分[J].中华肝胆外科杂志,2021,27:169-174.
He K,He YZ,Hu ZM,et al.Risk factors on liver cancer recurrence after radiofrequency ablation and establishment of a preoperative prediction score[J].Chin J Hepatobiliary Surg,2021,27:169-174.
[8]黄职妹,宁额尔敦巴格,李 慧,等.CT引导下人工腹水结合三维可视化系统辅助射频消治疗难消融复发性肝癌[J].介入放射学杂志,2022,31:387-393.
Huang ZM,Ning EEDBG,Li H,et al.CT-guided artificial ascites combined with three-dimensional visualization system-assisted radiofrequency ablation for refractory recurrent hepatocellular carcinoma[J].J Interv Radiol,2022,31:387-393.
[9]Chen J,Peng K,Hu D,et al.Tumor location influences oncologic outcomes of hepatocellular carcinoma patients undergoing radiofrequency ablation[J].Cancers,2018,10:378.
[10]Lu DS,Raman SS,Limanond P,et al.Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors[J].J Vasc Interv Radiol,2003,14:1267-1274.
[11]中国抗癌协会肿瘤消融治疗专业委员会,中国临床肿瘤学会(CSCO)肿瘤消融治疗专家委员会,中国医师协会肿瘤消融治疗技术专家组.CT引导下热消融治疗原发性肝癌中国专家共识[J].中华内科杂志,2023,62:647-660.
The Society of Tumor Ablation Therapy of the Chinese Anti-Cancer Association,The Ablation Expert Committee of the Chinese Society of Clinical Oncology,The Expert Group on Tumor Ablation Therapy of the Chinese Medical Doctors.Chinese expert consensus on CT-guided thermal ablation treatment of primary liver cancer[J].Chin J Intern Med,2023,62:647-660.
[12]Kobayashi M,Hosaka T,Ikeda K,et al.Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively[J].Hepatol Res,2011,41:1036-1045.
[13]鲁 叶,韩少山,刘青光.肝细胞癌术后早期复发的高危因素及预测方法[J].临床肝胆病杂志,2024,40:2098-2103.
Nu Y,Han SS,Liu QG.High-risk factors and prediction methods for early recurrence of hepatocellular carcinoma after surgery[J].J Clin Hepatol,2024,40:2098-2103.
[14]Chen R,Hou B,Zhou Y,et al.Recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma:analysis of the pattern and risk factors[J].Front Oncol,2023,13:1018715.
[15]Cao S,Lyu T,Fan Z,et al.Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma:tumor recurrence or progression,survival and clinical significance[J].Cancer Imaging,2022,22:2.
[16]Jiang B,Zhao K,Yan K,et al.Percutaneous radiofrequency ablation near large vessels in beagle livers:the impact of time and distance on the ablation zone[J].Int J Hyperthermia,2021,38:1263-1270.
[17]Doyle A,Gorgen A,Muaddi H,et al.Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients[J].J Hepatol,2019,70:866-873.
[18]Tsuchiya K,Asahina Y,Tamaki N,et al.Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma[J].Liver Transpl,2014,20:291-297.
[19]Zheng L,Li HL,Guo CY,et al.Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas[J].Korean J Radiol,2018,19:237-246.
[20]Imamura J,Tateishi R,Shiina S,et al.Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma[J].Am J Gastroenterol,2008,103:3057-3062.
[21]Hermida M,Cassinotto C,Piron L,et al.Multimodal percutaneous thermal ablation of small hepatocellular carcinoma:predictive factors of recurrence and survival in western patients[J].Cancers(Basel),2020,12:313.
[22]Lin YM,Paolucci I,O'connor CS,et al.Ablative margins of colorectal liver metastases using deformable CT image registration and autosegmentation[J].Radiology,2023,307:e221373.
[23]Li FY,Li JG,Wu SS,et al.An optimal ablative margin of small single hepatocellular carcinoma treated with image-guided percutaneous thermal ablation and local recurrence prediction base on the ablative margin:a multicenter study[J].J Hepatocell Carcinoma,2021,8:1375-1388.
[24]Laimer G,Schullian P,Jaschke N,et al.Minimal ablative margin(MAM)assessment with image fusion:an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation[J].Eur Radiol,2020,30:2463-2472.
[25]Lehmann KS,Ritz JP,Valdeig S,et al.Ex situ quantification of the cooling effect of liver vessels on radiofrequency ablation[J].Langenbecks Arch Surg,2009,394:475-481.
[26]Du P,Chen Z,Yuwen C,et al.Development and validation of an algorithm model for predicting heat sink effects during pulmonary thermal ablation[J].Curr Med Imaging,2023,Epub ahead of print.
[27]Lehmann KS,Poch FG,Rieder C,et al.Minimal vascular flows cause strong heat sink effects in hepatic radiofrequency ablation ex vivo[J].J Hepatobiliary Pancreat Sci,2016,23:508-516.
[28]傅晓华,罗 纯,高思明,等.干扰素治疗慢性乙型肝炎疗效预测人工神经网络模型的建立与应用[J].中国药房,2021,32:1257-1261.
Fu XH,Luo C,Gao SM,et al.Establishment and application of artificial neural network model in predicting clinical efficacy of interferon for chronic hepatitis B[J].China Pharm,2021,32:1257-1261.
(收稿日期:2025-04-06)
(本文编辑:茹 实)

相似文献/References:

[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
　GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(06):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
　SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(06):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
　CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(06):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
　WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(06):535.
[5]蒲红.上海市第二届射频消融疑难病例研讨会纪要[J].介入放射学杂志,1997,(01):63.
[6]蒲红,尹炯,王咏梅,等.显性间隔房室旁路的射频消融[J].介入放射学杂志,1997,(02):104.
[7]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
　WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(06):442.
[8]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[9]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[10]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
　ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(06):185.
[11]许 斌,张 政.肝细胞癌射频消融进展[J].介入放射学杂志,2025,34(10):1140.[doi:10.3969/j.issn.1008-794X.2025.10.019]
　XU Bin,ZHNAG Zheng..Progress in radiofrequency ablation for hepatocellular carcinoma[J].J Intervent Med,2025,34(06):1140.[doi:10.3969/j.issn.1008-794X.2025.10.019]
[12]沈丹萍,奚 静,牟佳怡,等.肝细胞癌患者射频消融后的预后预测列线图构建与验证[J].介入放射学杂志,2026,(04):424.[doi:10.3969/j.issn.1008-794X.2026.04.015 ]
　SHEN Danping,XI Jing,MOU Jiayi,et al.Construction and validation of a nomogram model used for predicting prognosis in patients with hepatocellular carcinoma after receiving radiofrequency ablation[J].J Intervent Med,2026,(06):424.[doi:10.3969/j.issn.1008-794X.2026.04.015 ]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金(62261044)
通信作者: 陈 勇 E-mail:chenyong6981@sina.com
更新日期/Last Update: 2026-05-25